Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-12-05

FDA Approved: GLIADEL — Supplemental Application (Azurity Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for GLIADEL (carmustine) submitted by Azurity Pharmaceuticals, Inc., resulting in changes to the labeling for the pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GLIADEL (Carmustine)

Snippet

SUPPL AP for GLIADEL (CARMUSTINE)